Back to top
more

Edwards Lifesciences (EW)

(Delayed Data from NYSE)

$78.61 USD

78.61
3,921,116

-0.63 (-0.80%)

Updated Aug 6, 2025 04:00 PM ET

After-Market: $78.62 +0.01 (0.01%) 6:16 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (148 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Hill-Rom (HRC) Stock Down With Dull Patient Support Systems

by Zacks Equity Research

Hill-Rom's (HRC) Patient Support Systems revenue decreases due to the adverse effect of the WatchChild and Architectural Products divestitures along with lower rental revenues.

    Zacks Equity Research

    LabCorp's $1.2 Billion Chiltern Buyout Gets FTC Approval

    by Zacks Equity Research

    The Federal Trade Commission (FTC) has granted LabCorp's (LH) request for an early closure of Chiltern's acquisition under HSR Act.

      Zacks Equity Research

      Chemed (CHE) on Growth Track With VITAS & Roto-Rooter Arms

      by Zacks Equity Research

      The raised outlook for both Roto-Rooter unit and the bottom line indicate Chemed's (CHE) estimate of improved operating results in the upcoming quarters.

        Zacks Equity Research

        Align Technology-Patterson Dental Deal Expands iTero Reach

        by Zacks Equity Research

        Align Technology (ALGN) progresses with a slew of developments in the scanners and services segment.

          Zacks Equity Research

          LabCorp to Add ChromaDex's Arm, Inorganic Expansion On Track

          by Zacks Equity Research

          LabCorp's (LH) decision to buy the analytical testing services arm of ChromaDex should fortify its Covance Food Solutions business.

            Zacks Equity Research

            Thermo Fisher's Patheon Buyout Gains Antitrust Clearance

            by Zacks Equity Research

            Thermo Fisher (TMO) gets antitrust clearance to move a step closer toward completion of Patheon acquisition.

              Kevin Cook headshot

              Bull of the Day: Edwards Lifesciences (EW)

              by Kevin Cook

              The world leader in non-surgical heart valve replacement keeps the "beat and raise" going with innovation and execution

                Zacks Equity Research

                Here's Why Investors Should Buy Amedisys (AMED) Right Now

                by Zacks Equity Research

                Strength in Hospice and Personal Care businesses offset the weakness in Amedisys' (AMED) Home Health Medicare business.

                  Zacks Equity Research

                  Align Technology's Invisalign Sales Strong Amid Margin Woes

                  by Zacks Equity Research

                  Align Technology's (ALGN) huge InvisAlign prospects in North America and international regions render optimism. However, escalating costs and expenses put pressure on the company's margins.

                    Zacks Equity Research

                    LabCorp Partners OmniSeq to Grow in Immuno-Oncology Space

                    by Zacks Equity Research

                    LabCorp (LH) decides to distribute OmniSeq's molecular diagnostics assays in the United States and beyond to grow in immuno-oncology space.

                      Zacks Equity Research

                      CVS Health (CVS) Releases Encouraging Flu Shot Survey Data

                      by Zacks Equity Research

                      CVS Health's (CVS) survey on flu vaccination came up with positive outcome. The data confirms untapped opportunities in the flu vaccine market.

                        Zacks Equity Research

                        Here's Why Investors Should Buy BioTelemetry (BEAT) Now

                        by Zacks Equity Research

                        BioTelemetry's (BEAT) buyout of LifeWatch AG has expanded its product portfolio and customer base in the cardiac monitoring and diagnostic services space.

                          Zacks Equity Research

                          Zacks.com featured highlights: SP Plus Corp, Edwards Lifesciences, Magna International and NVIDIA

                          by Zacks Equity Research

                          Zacks.com featured highlights: SP Plus Corp, Edwards Lifesciences, Magna International and NVIDIA

                            Zacks Equity Research

                            Stryker (SYK) to Gain From Solid Portfolio and Acquisitions

                            by Zacks Equity Research

                            Stryker's (SYK) diverse product portfolio alongside acquisition-driven strategy would continue to boost growth prospects. However, competition in the Chinese market raise concern.

                              Tirthankar Chakraborty headshot

                              4 Stocks to Buy as Q2 Earnings Season Nears Close

                              by Tirthankar Chakraborty

                              Earnings growth is considered to be the most significant variable in influencing the share price.

                                Zacks Equity Research

                                Accelerate Diagnostics (AXDX) In Focus: Stock Rises 5.1%

                                by Zacks Equity Research

                                Accelerate Diagnostics (AXDX) was a big mover last session, as the company saw its shares rise more than 5% on the day.

                                  Zacks Equity Research

                                  Fluidigm (FLDM) Licenses CFTR Assay From Baylor Genetics

                                  by Zacks Equity Research

                                  Fluidigm (FLDM) has licensed rights to commercialize the cystic fibrosis transmembrane conductance regulator. The company is focused on improving its Juno automated microfluidic system.

                                    Zacks Equity Research

                                    Allscripts, Elligo Health Enter in Strategic Partnership

                                    by Zacks Equity Research

                                    Allscripts' (MDRX) Strategic Partnership with Elligo Health would aid the company in capturing the Clinical Research Organizations' lucrative market.

                                      Zacks Equity Research

                                      Walgreens' (WBA) Research Website to Add Value in Healthcare

                                      by Zacks Equity Research

                                      Walgreens Boots Alliance's (WBA) Center for Health & Wellbeing Research is set to improve patient care and outcomes while reducing health care costs at the same time.

                                        Zacks Equity Research

                                        Omnicell Upgrades Web Portal, Grows in Medication Management

                                        by Zacks Equity Research

                                        Omnicell (OMCL) makes progress in medicare adherence with four new enhancements to its web portal PMAP.

                                          Zacks Equity Research

                                          Henry Schein to Offer CAEK's HIPAA Software LayerCompliance

                                          by Zacks Equity Research

                                          Henry Schein (HSIC) inks an agreement to distribute CAEK's HIPAA related software, LayerCompliance.

                                            Zacks Equity Research

                                            Here's Why Investors Should Buy Edwards Lifesciences Now

                                            by Zacks Equity Research

                                            Market is upbeat about Edwards Lifesciences's (EW) recent FDA approvals and strong 2017 guidance.

                                              Zacks Equity Research

                                              Here's Why You Should Invest in IDEXX Laboratories (IDXX) Now

                                              by Zacks Equity Research

                                              IDEXX Laboratories (IDXX) rides high on strength across all segments, with significant contributions from the Companion Animal Group business. Moreover, a raised guidance buoys optimism.

                                                Zacks Equity Research

                                                Is Edwards Lifesciences Corporation (EW) a Great Growth Stock?

                                                by Zacks Equity Research

                                                Edwards Lifesciences Corporation (EW) is a company that might be well-positioned for future earnings growth.

                                                  Zacks Equity Research

                                                  Here's Why Investors Should Buy Align Technology (ALGN) Now

                                                  by Zacks Equity Research

                                                  Align Technology (ALGN) continues to ride high on robust growth in the Invisalign space.